BP
CVS icon

Ballentine Partners’s CVS Health CVS Stock Holding History

Ballentine Partners’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$801K Buy
7,740
+619
+9% +$55.3K 0.01% 422
2026
Q1 		$511K Sell
7,121
-325
-4% -$25K 0.01% 522
2025
Q4 		$591K Buy
7,446
+2,004
+37% +$158K 0.01% 451
2025
Q3 		$410K Sell
5,442
-633
-10% -$43.4K 0.01% 574
2025
Q2 		$419K Sell
6,075
-2,182
-26% -$143K 0.01% 545
2025
Q1 		$559K Buy
8,257
+2,943
+55% +$176K 0.01% 413
2024
Q4 		$239K Buy
5,314
+793
+18% +$44.5K ﹤0.01% 705
2024
Q3 		$284K Sell
4,521
-7,938
-64% -$463K ﹤0.01% 613
2024
Q2 		$736K Buy
12,459
+4,238
+52% +$265K 0.01% 325
2024
Q1 		$656K Sell
8,221
-2,835
-26% -$217K 0.01% 337
2023
Q4 		$873K Sell
11,056
-4,249
-28% -$302K 0.02% 252
2023
Q3 		$1.07M Buy
15,305
+6,733
+79% +$477K 0.03% 192
2023
Q2 		$593K Sell
8,572
-2,728
-24% -$194K 0.01% 276
2023
Q1 		$840K Sell
11,300
-1,742
-13% -$146K 0.02% 219
2022
Q4 		$1.22M Buy
13,042
+1,501
+13% +$145K 0.04% 150
2022
Q3 		$1.1M Buy
11,541
+2,682
+30% +$265K 0.04% 145
2022
Q2 		$821K Sell
8,859
-165
-2% -$16.1K 0.03% 173
2022
Q1 		$913K Buy
9,024
+793
+10% +$83.3K 0.03% 183
2021
Q4 		$849K Sell
8,231
-194
-2% -$17.9K 0.03% 199
2021
Q3 		$715K Buy
8,425
+20
+0.2% +$1.68K 0.02% 190
2021
Q2 		$702K Sell
8,405
-666
-7% -$54.5K 0.02% 192
2021
Q1 		$682K Buy
9,071
+625
+7% +$45.5K 0.03% 186
2020
Q4 		$577K Sell
8,446
-1,348
-14% -$87.7K 0.02% 197
2020
Q3 		$572K Sell
9,794
-3,003
-23% -$187K 0.03% 193
2020
Q2 		$831K Sell
12,797
-2,256
-15% -$142K 0.04% 154
2020
Q1 		$893K Buy
15,053
+5,617
+60% +$375K 0.05% 131
2019
Q4 		$700K Sell
9,436
-333
-3% -$23.4K 0.03% 192
2019
Q3 		$616K Buy
9,769
+2,258
+30% +$134K 0.03% 192
2019
Q2 		$409K Buy
7,511
+2,876
+62% +$155K 0.02% 241
2019
Q1 		$250K Sell
4,635
-4,273
-48% -$264K 0.01% 277
2018
Q4 		$584K Buy
8,908
+2,066
+30% +$154K 0.03% 177
2018
Q3 		$539K Buy
6,842
+443
+7% +$31.7K 0.03% 189
2018
Q2 		$412K Buy
6,399
+473
+8% +$31.2K 0.02% 211
2018
Q1 		$369K Sell
5,926
-3,277
-36% -$235K 0.02% 228
2017
Q4 		$667K Buy
9,203
+408
+5% +$29.7K 0.04% 158
2017
Q3 		$716K Sell
8,795
-3,845
-30% -$304K 0.04% 156
2017
Q2 		$998K Buy
12,640
+4,110
+48% +$325K 0.07% 127
2017
Q1 		$669K Buy
8,530
+2,075
+32% +$166K 0.05% 99
2016
Q4 		$517K Sell
6,455
-266
-4% -$21.5K 0.04% 107
2016
Q3 		$598K Sell
6,721
-177
-3% -$16.7K 0.05% 85
2016
Q2 		$660K Sell
6,898
-206
-3% -$20.5K 0.06% 88
2016
Q1 		$737K Buy
7,104
+1,576
+29% +$153K 0.06% 85
2015
Q4 		$541K Buy
5,528
+238
+4% +$23.3K 0.05% 90
2015
Q3 		$511K Buy
5,290
+29
+0.6% +$3.05K 0.05% 85
2015
Q2 		$552K Hold
5,261
– – 0.05% 82
2015
Q1 		$543K Buy
5,261
+1,291
+33% +$131K 0.05% 82
2014
Q4 		$382K Hold
3,970
– – 0.04% 112
2014
Q3 		$316K Hold
3,970
– – 0.04% 112
2014
Q2 		$299K Sell
3,970
-81
-2% -$6.12K 0.04% 113
2014
Q1 		$304K Buy
4,051
+51
+1% +$3.6K 0.04% 112
2013
Q4 		$286K Hold
4,000
– – 0.03% 120
2013
Q3 		$227K Buy
+4,000
New +$238K 0.03% 128

Other funds holding CVS

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CF
Canoe Financial Calgary, Alberta, Canada $8.07B AUM 25.47% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
CAM
Cacti Asset Management Atlanta, Georgia $1.99B AUM 86.33% 1-Year Est. Return

Ballentine Partners's CVS Position: Q2 2026 in Review

Ballentine Partners increased its CVS Health (CVS) stake by 8.7% in Q2 2026, buying an estimated $55.3K and bringing the position to 7,740 shares worth $801K. The position accounts for 0.01% of the portfolio, ranked #422.

Ballentine Partners first reported a position in CVS in Q3 2013 and has held it in 52 quarters since. The position peaked at $1.22M in Q4 2022. 348 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • Ballentine Partners held 7,740 shares of CVS Health worth $801K as of Q2 2026.
  • Ballentine Partners bought 619 CVS Health shares in Q2 2026, an estimated $55.3K.
  • CVS Health made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #422 holding.
  • Ballentine Partners first reported a position in CVS Health in Q3 2013 and has held it in 52 quarters since.
  • Ballentine Partners's CVS Health position peaked at $1.22M in Q4 2022.
  • 348 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.